

July 16, 2015



XOMA to Announce Second Quarter 2015 Financial Results and Host Webcast on August 6

BERKELEY, Calif., July 16, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Thursday, August 6, 2015, at 4:30 p.m. Eastern daylight time to discuss second quarter 2015 financial results and provide an update on gevokizumab's global clinical programs.

The webcast can be accessed via the Investors & Media section of XOMA's website at <http://investors.xoma.com/events.cfm> and will be available for replay until close of business on November 6, 2015. Telephone numbers for the live audiocast are 877-369-6589 (U.S./Canada) and 408-337-0122 (international).

The Company also confirms its gevokizumab development partner, Servier, remains on track to report top-line pivotal Phase 3 EYEGUARD™-B data the week of July 20, 2015.

About XOMA Corporation

XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, including allosteric modulating antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Servier through a global Phase 3 program for Behçet's disease uveitis and non-infectious uveitis. XOMA also has an ongoing Phase 3 study of gevokizumab in pyoderma gangrenosum. Additionally, XOMA's scientific research has produced the XMet platform, which consists of three classes of Selective Insulin Receptor Modulators (SIRMs) antibodies. XOMA 358, the lead antibody in the XMetD program, is an allosteric modulating monoclonal antibody that reduces both the binding of insulin to its receptor and down-regulates insulin signaling and could have a major effect on the treatment of abnormal metabolic states. XOMA 358 recently completed Phase 1 testing. For more information, visit www.xoma.com.

Investor Contacts:

Ashleigh Barreto, XOMA Corporation
510-204-7482
barreto@xoma.com

Juliane Snowden, The Oratorium Group, LLC
jsnowden@oratoriumgroup.com

Media Contact:
Ryan Flinn, W₂O Group
415-946-1059
rflinn@w2ogroup.com

Source: XOMA Corporation